Who was studied, and how
Two numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 4 other studies
people with type 2 diabetes, in this paper
Among background empagliflozin dose (Study 1: ≥1000 mg/day metformin and empagliflozin 10 mg/day), the trial randomly assignedassigned by chance
lobeglitazone 0.5 mg/day
placebo
May have lowered long-term blood sugar−0.71
randomised · one subgroupAmong background empagliflozin dose (Study 2: ≥1000 mg/day metformin and empagliflozin 25 mg/day), the trial randomly assignedassigned by chance
lobeglitazone 0.5 mg/day
placebo
May have lowered long-term blood sugar−0.62
randomised · one subgroupthe abstract, start to end
… of the background empagliflozin dose (-0.71%; 95% confidence interval, -0.88 to -0.55; p < 0.001 in Study 1 and -0.62%; -0.79 to -0.45; p < 0.001 in …
← favours treatmentfavours comparator →
could be chanceChange from baseline in glycated haemoglobin (HbA1c) at 24 weekslobeglitazone 0.5 mg/day vs placebo, in background empagliflozin dose (Study 1: ≥1000 mg/day metformin and empagliflozin 10 mg/day)
−0.71−0.88 to −0.55
Change from baseline in glycated haemoglobin (HbA1c) at 24 weekslobeglitazone 0.5 mg/day vs placebo, in background empagliflozin dose (Study 2: ≥1000 mg/day metformin and empagliflozin 25 mg/day)
−0.62−0.79 to −0.45
ThiazolidinedionesAdverse events & safety
Thiazolidinediones × adverse events & safetyharms?mixed
unlikelylikely
0.000.00 without it
← favours treatmentfavours comparator →
1 / 6